SG168430A1 - Molecular signature of human lung cancer initiating cells - Google Patents

Molecular signature of human lung cancer initiating cells

Info

Publication number
SG168430A1
SG168430A1 SG200904945-3A SG2009049453A SG168430A1 SG 168430 A1 SG168430 A1 SG 168430A1 SG 2009049453 A SG2009049453 A SG 2009049453A SG 168430 A1 SG168430 A1 SG 168430A1
Authority
SG
Singapore
Prior art keywords
lung cancer
human lung
initiating cells
molecular signature
cancer initiating
Prior art date
Application number
SG200904945-3A
Inventor
Bing Lim
Wencai Zhang
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG200904945-3A priority Critical patent/SG168430A1/en
Priority to PCT/SG2010/000168 priority patent/WO2010126452A1/en
Publication of SG168430A1 publication Critical patent/SG168430A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

According to the invention there is provided a biomarker, CD166, capable of distinguishing lung cancer stem cells that initiate tumerogenesis. Antagonists to lung cancer cells expressing CD166 able to decrease the tumorigenesis of lung cancer both in vitro and in vivo providing compounds to treat lung cancer. Lung cancer stem cells and cell lines, lung cancer spheres and tissue for screening of antagonists to lung cancer stem cells. Figure 9B
SG200904945-3A 2009-04-29 2009-07-22 Molecular signature of human lung cancer initiating cells SG168430A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SG200904945-3A SG168430A1 (en) 2009-07-22 2009-07-22 Molecular signature of human lung cancer initiating cells
PCT/SG2010/000168 WO2010126452A1 (en) 2009-04-29 2010-04-29 Molecular signature of human lung cancer initiating cells and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG200904945-3A SG168430A1 (en) 2009-07-22 2009-07-22 Molecular signature of human lung cancer initiating cells

Publications (1)

Publication Number Publication Date
SG168430A1 true SG168430A1 (en) 2011-02-28

Family

ID=43032403

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200904945-3A SG168430A1 (en) 2009-04-29 2009-07-22 Molecular signature of human lung cancer initiating cells

Country Status (2)

Country Link
SG (1) SG168430A1 (en)
WO (1) WO2010126452A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG190793A1 (en) 2010-11-11 2013-07-31 Agency Science Tech & Res Targeting metabolic enzymes in human cancer
TWI485253B (en) * 2011-11-08 2015-05-21 Univ Nat Cheng Kung Methods and kits for detecting circulating cancer stem cells
US20160145580A1 (en) * 2013-06-18 2016-05-26 Agency For Science, Technology And Research Method of culturing cancer stem cells
US9778263B2 (en) 2013-11-13 2017-10-03 General Electric Company Quantitative in situ characterization of biological samples
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
FR3067466B1 (en) * 2017-06-08 2021-09-03 Carcidiag Biotechnologies METHOD OF ISOLATION AND DETECTION OF CANCERIOUS STEM CELLS
CN111344570A (en) * 2017-06-08 2020-06-26 卡西迪亚生物技术公司 Method for isolating and detecting cancer stem cells
CN108949754A (en) * 2018-07-31 2018-12-07 江苏省人民医院 IGSF3 gene and its shRNA sequence and the application in anti-human lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225294A1 (en) * 2002-05-03 2003-11-17 Raven Biotechnologies, Inc. Alcam and alcam modulators
JP5612247B2 (en) * 2005-11-29 2014-10-22 独立行政法人科学技術振興機構 Monoclonal antibody against CD166 and production method thereof
GB0705775D0 (en) * 2007-03-26 2007-05-02 Affitech As Product

Also Published As

Publication number Publication date
WO2010126452A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
SG168430A1 (en) Molecular signature of human lung cancer initiating cells
WO2010017515A3 (en) Breast cancer specific markers and methods of use
HK1245147A1 (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
MX2011008221A (en) Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor.
MX2013002084A (en) Biomarkers and methods of treatment.
WO2011075731A3 (en) Tissue expanders and methods of use
EP2486149A4 (en) Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
HK1187377A1 (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
UA109271C2 (en) Combination of phytocannabinoids and temosolamide for treating glioma
AU324582S (en) Footwear outsole
AU328545S (en) Footwear sole
MX2014005800A (en) Human notch receptor mutations and their use.
AU2012305327B2 (en) Polymer-type fluorescent molecule probe
SI2519527T1 (en) Thienoš2,3-bćpyridinedione activators of ampk and therapeutic uses thereof
WO2011020107A3 (en) Compositions and methods for detection and treatment of breast cancer
GB201608839D0 (en) Biomarkers useful for detectionof types, grades and stages of human breast cancer
MX344303B (en) Methods of providing weight loss therapy in patients with major depression.
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2013019945A3 (en) Method for selection of chemotherapeutic agents for adenocarcinoma cancer
MX358726B (en) Predictive biomarker of survival in the treatment of renal cell carcinoma.
EP2255835A4 (en) Medical instrument, medical material, and method for production of the medical instrument and medical material
PT2473854T (en) Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer
WO2009091230A3 (en) Protein marker for breast-cancer monitoring, diagnosis and screening, and a breast-cancer monitoring, diagnosis and screening method using the same